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Abstract. Background: The associations between B-cell
lymphoma 2 (BCL-2) and multi-drug resistance associated P-
glycoprotein (MDR1) expressions and chemoradiotherapy
outcome of patients with non-small cell lung cancer (NSCLC)
were analysed. Patients and Methods: Thirty-two NSCLC
patients were treated with paclitaxel-based chemoradiotherapy.
The tumour expressions of BCL-2 and MDR1 were analysed
by means of immunohistochemistry with regard to the clinical
response and survival data. Results: Partial remission and
stable disease were achieved in 19 (59%) and 10 (31%) cases,
respectively. Significant differences in progression-free survival
were observed between responders and non-responders (13.7
vs. 6.0 months, p=0.028), and between patients with or without
a gross tumour volume (GTV) shrinkage (GTV>50 13.7 vs. 6.0
months, p=0.009). Overexpression of BCL-2 and of MDR1 was
observed in 6 (21.4%) cases each. Overexpression of both
markers together was associated with poor response (GTV
reduction: p=0.005; RECIST: p=0.023) and lower progression-
free survival (overexpression of both, low expression of both,
mixed: 3.1, 13.4, 4.1 months, respectively, p<0.001).
Conclusion: BCL-2 and MDR1 overexpression may predict the
inefficacy of paclitaxel-based chemoradiotherapy. 
Lung cancer is the most frequent tumour worldwide. Molecular
markers may be of prognostic value, especially in the early
stages. The identification of specific genes that may be targeted
by new therapies appears to be a potentially rewarding approach.
Individualized combinations of various treatment
procedures for locally advanced lung cancer tend to improve
local control and survival. Such favourable results may be
achieved through the application of increasingly more
sophisticated chemotherapeuticals and their combinations
with radiotherapy (1, 2). Radiosensitization has been
reported to increase therapy efficacy, but it may also increase
therapy-induced toxicity (1, 3). 
The most frequently applied third-generation
chemotherapeuticals are the taxanes, which have been
demonstrated in clinical trials to be widely effective in
advanced non-small cell lung cancer (NSCLC) (1, 2). The
prototype of the taxane family is paclitaxel, an excellent
radiosensitizer (1, 2, 4-6). In designing the optimum
individual treatment planning, including selection of an
effective chemotherapeutical and the anticipation of potential
radioresistance, the physician may be aided by predictive
markers (7-20).
Multi-drug resistance-associated P-glycoprotein (MDR1, P-
gp170, ABCB1) is a well-known plasma membrane drug efflux
pump that is associated with resistance to a wide range of
anticancer drugs. Paclitaxel is a substrate of this transporter
system. The overexpression of MDR1 may play an important
role in the paclitaxel-resistance of lung cancer (21-23).
The oncogenic protein B-cell lymphoma 2 (BCL-2),
which plays a central role in apoptosis, has been found to
correlate with the prognosis of NSCLC. Most studies have
suggested a more favourable prognosis in BCL-2-positive
cases (7-10), but poorer survival rates of patients with higher
BCL-2 expression have also been reported (11-13).
The predictive role of BCL-2 has also been examined in
various tumour types. The association between the response
to platinum-based chemoradiotherapy and apoptosis-related
proteins is unclear. No correlation was found in cancer of the
bladder (14), the oesophagus (15) or the rectum (16). The
overexpression of BCL-2 predicted a more favourable
outcome in head and neck (17) and lung (18) cancer, but an
unfavourable effect has been described for oropharyngeal
(19) and lung cancer patients (11).
The aim of this study was to analyse the associations
between the expressions of BCL-2 and MDR1 with the
clinical outcome of paclitaxel-based chemoradiotherapy in
patients with NSCLC.
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Patients and Methods
The study was conducted in full accordance with the institutional
regulations and all the patients gave their written informed consent
for participation in the chemotherapy and radiotherapy.
Study population. Patients receiving chemoradiotherapy for primary
unresectable or potentially resectable NSCLC at the Department of
Oncotherapy in the period between December 2006 and June 2010
were eligible for participation in this study. All tumours were proven
by histological verification. The staging procedures were based on
the conventional protocol (chest computer tomography (CT),
abdominal ultrasound/CT, brain CT, bone scan, bronchoscopy) and
on induction chemotherapy. For each patient, the treatment plan was
designed by a multidisciplinary team. 
Systemic treatment and radiotherapy. During the radiotherapy, all the
patients received concomitant taxane-based chemotherapy (weekly
paclitaxel 100 mg/m2 in 4-6 cycles, depending on toxicity). Of the 19
patients (stage IIIB) who completed induction chemotherapy (1 or 2
cycles), 17 (89.5%) received a taxane-based chemotherapy regimen
(paclitaxel 175 mg/m2 with carboplatin 400 mg/m2 or docetaxel 
75 mg/m2 with cisplatin (CDDP) 75 mg/m2, at 3-week intervals),
while 2 patients received a gemcitabine-based regimen (gemcitabine
1250 mg/m2 on days 1 and 8, CDDP 70 mg/m2 on day 1, and then at
3-week intervals) for at least 4 weeks prior to the concomitant
chemoradiotherapy. After completion of the chemoradiotherapy,
additional consolidation chemotherapy was administered in 18 cases
(paclitaxel 175 mg/m2 with carboplatin 400 mg/m2 or docetaxel 
75 mg/m2 with CDDP 75 mg/m2, at 3-week intervals).
CT-based three-dimensional treatment planning and conformal
radiotherapy were performed in all cases, with use of an individual
immobilization system. The planning target volume encompassed
the macroscopic lung cancer, the involved mediastinal and ipsilateral
hilar lymph node regions and the safety zone, according to the local
protocol. The initial radiation dose was 25×1.8 Gy; after a repeated
CT scan, depending on the tumour response, radiotherapy of the
reduced volume was continued at an average dose of 22-26 Gy
(with the exception of neoadjuvant therapy). 
Response analysis. During the treatment, following the administration
of a 45 Gy dose, and 4-6 weeks after the completion of the
chemoradiotherapy regimen, clinical and diagnostic CT examinations
were performed. The CT scans were compared with the pretreatment
scans provided for radiotherapy-planning purposes. Response analysis
was carried out by means of two methods: the exact values of gross
tumor volume (GTV) and GTV1 were determined and the tumour
volume reduction was calculated (reductions in the ranges >50%, 50-
40% and <40% are referred to as GTV>50, GTV50-40 and GTV<40,
respectively), additionally, the CT scans were analysed according to
the RECIST criteria system (24). 
Immunohistochemistry. Before the chemoradiotherapy, immuno-
histochemical staining of the biopsy samples was performed to
quantify the BCL-2 and MDR1 expressions. Histological samples
from 28 out of the 32 evaluated patients were examined prospectively
for BCL-2 and MDR1 (clone 494) expressions. (The histological
samples from 4 patients were used for K-RAS analysis and the
remaining material was not sufficient for further
immunohistochemical analysis.) Immunohistochemical studies were
carried out on paraffin sections by an indirect peroxidase method.
Sections were cut 4-μm-thick. Deparaffinizing, rehydrating and
antigen retrieval were performed in a PraeTreatment module (Dako,
Glostrup, Denmark) (20 min, 98 °C), using the 3in (pH 6.0) solution
produced by LabVision (Fremont, CA, US). The endogenous
peroxidase activity was blocked with hydrogen peroxide (3%, 10 min)
and a solution of milk powder (in 1% phosphate-buffered saline, 
10 min) was used as protein block. The Real-Envision (DAB) kit
(Dako) was used as the labelling system. A semiquantitative scoring
method was used to rate immunohistochemical staining: positive cell
rates in the ranges 0-1%, 2-33%, 34-66% and >66% were scored as 0,
1+, 2+ and 3+, respectively. The intensity staining score was 2+
(moderate) in all cases. Any cytoplasmic staining with BCL-2 was
considered positive. BCL-2 and MDR1 expression at a level of 2-3+
was classified as high expression (Figure 1). 
Statistical analysis. All analyses were carried out using SPSS
version 15.0 for Windows (SPSS Inc., Chicago, IL, USA). The main
outcome measures were the tumour response and the time to
progression. The associations between the molecular marker
expressions and clinical factors, tumour response, local relapse and
presence of distant metastasis within 6 months were evaluated with
the chi-square test, while those with age were assessed with the one-
way ANOVA test. In terms of both progression-free (PFS) and
overall survival (OS), the outcome was analysed by Kaplan-Meier
analysis (pairwise comparisons – Breslow test).
Results
Patient characteristics, response and survival. Thirty-two
patients received paclitaxel-based chemoradiotherapy, at a
mean dose of 64.0 (45.0-70.0) Gy, in combination with a
mean of 5 (4-6) cycles of chemotherapy. The mean age
(±SD) of the patients was 58.9 (±6.2) years; 21 (66%) were
men. Most of the patients had stage IIIB cancer (75%).
Neoadjuvant treatment was administered to 5 patients with
stage IIIA and 3 with stage IIB sulcus superior (Pancoast)
tumours, respectively. The performance status of the patients
was good (ECOG 0 and 1, 44% and 56%). The histological
type was adenocarcinoma in 20 (62.5%) and squamous cell
carcinoma in 12 cases (37.5%).
After the chemoradiotherapy, surgical treatment was
possible in 10 cases (31%) and 18 patients (56%) received
consolidation chemotherapy. At the time of the last follow-up
(median 17 months), 14 (44%) patients had died, 12 due to
lung cancer, 1 following the surgical procedure due to
pulmonary embolization, and another after the
chemoradiotherapy due to pneumonitis, all in stage IIIB.
Fifteen patients (47%) developed local or distant recurrence. 
Of the 32 lung cancer patients, 19 (59%) exhibited partial
remission (PR), while 10 (31%) had stable disease (SD). The
condition of all three patients (10%) with progressive disease
(PD; 2 locoregional and 1 distant metastasis) worsened
during the treatment. There was a significant difference in
the duration of PFS between the responders (PR) and the
non-responders (SD+PD) (13.7 vs. 6.0 months, p=0.028), but
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there was no significant difference in the OS duration (29.1
vs. 15.7 months, p=0.256). Our analysis of the relationship
between PFS and OS and the tumour volume shrinkage
(GTV>50, GTV50-40 and GTV40>) indicated that the PFS
results were more favourable in patients with than in those
without tumour shrinkage (GTV>50 13.7 vs. 6.0 months,
p=0.009; GTV50-40 13.43 vs. 4.8 months, p=0.008; GTV<40
13.4 vs. 4.8 months, p=0.008), but no association was found
between the OS and the shrinkage (GTV>50 29.1 vs. 26.6
months, p=0.979; GTV50-40 26.6 vs. 22.0 months, p=0.656;
GTV<40 26.7 vs. 29.1 months, p=0.846). Of the 10 patients
who underwent surgery, 5 (50%) exhibited pathologically
complete remission and the other 5 a partial pathological
response. The difference between the surgical and non-
surgical populations was not significant from the point of
view of their survival (29.1 vs. 22.1 months, p=0.119), but
there was a more favourable trend in the outcome after
surgery. The OS rate correlated significantly only with
consolidation chemotherapy (survival with or without
chemotherapy, 13.4 vs. 4.8 months, p<0.001), and the
duration of PFS was also longer (29.4 vs. 11.3 months,
p<0.001).
Association of expression of drug resistance- and apoptosis-
related proteins with clinicopathological characteristics.
There were 16 (57.2%) BCL-2-negative and 19 (67.8%)
MDR1-negative cases. A low expression of BCL-2 and of
MDR1 was observed in 6 (21.4%) and 3 (10.7%) cases,
respectively. A high expression of BCL-2 and of MDR1 was
observed in 6 (21.4%) cases each. The tumour in three
(10.7%) patients displayed high expression of both markers
(Table I). There were no significant correlations between a
high expression of BCL-2 or MDR1 and other characteristics
of the patients (age, gender, stage or histology). 
Association of expression of drug resistance- and apoptosis-
related proteins with response and outcome of patients. A
high expression of both markers simultaneously was
significantly associated with a poor response to paclitaxel-
based chemoradiotherapy, when evaluated against either a
GTV reduction during therapy (p=0.019), or a tumour
response according to RECIST (p=0.005) (Table II). A high
expression of BCL-2 or of MDR1 was significantly
associated with a lower duration of PFS (BCL-2 high vs.
low/negative, 4.2 vs. 13.4 months p=0.025; MDR1 high vs.
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Figure 1. Immunohistochemistry of biopsy specimens. A: Moderate cytoplasmic positivity for MDR1 (original magnification ×224); B: moderate
nuclear and cytoplasmic positivity for BCL-2 (original magnification ×224). 
Table I. Distribution of BCL-2 and multi-drug resistance associated P-glycoprotein (MDR1) expression.
n=28 BCL-2 MDR1 BCL-2 and MDR1
Negative 1+ 2+/3+ Negative 1+ 2+/3+ Both low/neg Mixed expression Both 2+/3+
n 16 6 6 19 3 6 19 6 3
% 57.2 21.4 21.4 67.8 10.7 21.4 67.9 21.4 10.7
low/negative, 1.63 vs. 13.4 months, respectively, p<0.001),
whether evaluated separately or together (BCL-2 and MDR1
both high, both low/negative or mixed expression, 3.1, 13.4
and 4.1 months, respectively, p<0.001). PFS was shorter in
cases with MDR1-positive tumours than in those with
MDR1-negative ones (3.1 vs. 13.4 months p=0.003). In
patients with pathologically complete remission, both markers
were negative. No association was found between OS, the
appearance of early metastases (within 6 months) and the
expression of BCL-2 or MDR1. Local recurrence within 6
months was more frequent in patients with overexpression of
BCL-2 (p=0.0023) or of MDR1 (p=0.007). 
Discussion
The present study demonstrated that overexpression of the
evaluated anti-apoptotic and cell membrane proteins can help
predict the efficacy of paclitaxel-based chemoradiotherapy.
We observed a strong association between the concurrent
overexpression of BCL-2 and MDR1, and the tumour
response and PFS in NSCLC patients. The novelty of our
study lies in the analysis of the efficacy of paclitaxel and
concomitant radiotherapy in relation to the expressions of the
above markers.
We mainly used paclitaxel with radiotherapy or paclitaxel
in combination with carboplatin in the course of induction
and consolidation therapy. Paclitaxel stabilizes microtubules,
which blocks cell cycle progression in the most radiosensitive
G2-M phase, and also induces BCL-2 hyperphosphorylation,
resulting in its inactivation, thereby facilitating apoptosis (25,
26). In our cohort, those patients demonstrating no response
to paclitaxel-based chemoradiotherapy had a significantly
more unfavourable PFS, and a worse (although not
significantly) OS, which highlights the importance of
predicting the potentially non-responsive patient population.
We observed a significant association between the tumour
response, the reduced PFS and the overexpression of MDR1.
Preclinical data demonstrated that the increased activity of
the signalling pathway in paclitaxel-resistant cell lines was
directly attributable to the overexpression of MDR1. It was
reported that MDR1 may contribute to the multidrug
resistance of lung cancer (21-23).
The prognostic value of BCL-2 positivity has been
widely studied. Several papers have confirmed a more
favourable disease progression in patients with BCL-2-
positive tumours with either surgically resected (7) or
locally advanced (10) NSCLC, or even irrespective of the
stage (8, 9). However, some studies did not find a
significant association between BCL-2 expression and
survival (28, 29), or even reported a worse survival in the
event of high BCL-2 expression (11-13).
Considerably fewer studies have examined the
interaction between the expression of BCL-2 and the
outcome of oncological treatment, i.e. the role of BCL-2 in
predicting the tumour response, and yielded controversial
results (14-19). Jeong et al. treated NSCLC patients with
cisplatin-based chemoradiotherapy and observed that a high
expression of BCL-2 was significantly associated with a
longer survival and a better response to the treatment (18).
The findings of Fokkema et al. indicated a more favourable
PFS of patients with an overexpression of BCL-2 following
radiotherapy with or without carboplatin-based chemo-
radiotherapy, although they did not analyse the radiotherapy
and chemoradiotherapy cohorts separately (10). Hwang et
al. reported that BCL-2 expression predicted a poor
outcome for radiation-treated NSCLC patients (11). Our
own results revealed that, as compared with patients with a
negative or low BCL-2 expression, patients with an
overexpression of BCL-2 demonstrated a significantly
worse RECIST tumour response and a poorer PFS after
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Table II. Association of molecular marker expression (BCL-2, MDR1) with clinical outcome.
n=28 Response (RECIST) Volume change (%) PFS
Expression PR SD PD p-Value* >50 50-40 <40 p-Value* Months p-Value**
(median±S.D.)
BCL-2 
Neg/low 16 5 1 0.082 13 3 6 0.151 13.4±2.5 0.025
High 2 2 2 1 1 4 4.2±0.6
MDR1 
Neg/low 17 4 1 0.016 11 4 4 0.001 13.4±2.2 <0.001
High 1 3 2 3 - - 1.63±1.1
Both neg/low 15 3 1 0.005 13 3 3 0.019 13.4±0.2 <0.001
Mixed 3 3 - 1 1 4 4.1±1.9
Both high 0 1 2 0 0 3 3.1±1.4
*Chi-square test; **Kaplan-Meier; PR, partial remission; SD, stable disease; PD, progressive disease; PFS, progression-free survival. 
paclitaxel-based chemoradiotherapy, and in the event of the
overexpression of both MDR1 and BCL-2, the tumour
response was significantly poorer.
BCL-2 inhibits programmed cell death, and can be
associated with a more aggressive tumour cell phenotype,
with conseqvent resistance to treatment protocols based
on microtubule damage. The efficacy of radiotherapy-
induced apoptosis, and therefore the whole of the
treatment, may be reduced in tumours exhibiting an
overexpression of BCL-2 (11-13). The predictive value of
BCL-2, especially for radiotherapy combined with third-
generation chemotherapy, a prevalent advanced treatment
procedure, is still unclear. 
In our study, the overexpression of both biomarkers was
found in the patients with the poorest tumour response and
PFS. We hypothesize that a high MDR1 expression indicates
an enhanced drug efflux activity, leaving the cell without an
adequate amount of chemotherapeutic agent. A high BCL-2
expression, as an antiapoptotic mechanism, may inhibit
radiotherapy-induced programmed cell death (Figure 2). This
hypothesis is supported by the finding that both markers
were negative in tumours from patients demonstrating
complete pathological remission.
The overexpression of MDR1 in our cohort was associated
with a poorer tumour response. However, for patients with
an overexpression of BCL-2, but not of MDR1, there was a
slightly, although not significantly better therapeutic efficacy
as compared with patients displaying an overexpression of
both markers. We assume that paclitaxel terminated the
inhibition of apoptosis by hyperphosphorylating and
inactivating BCL-2, and thereby partially restoring
radiosensitivity (25, 27) (Figure 2).
Our findings demonstrate that the concomitant application
of paclitaxel and radiotherapy is potentially ineffective in the
treatment of NSCLC, leading to a shorter PFS and more
frequent local remission if the tumour indicates the
overexpression of both MDR1 and BCL-2. The findings
suggest that paclitaxel-based chemoradiotherapy is
questionable in this group of patients, who may benefit more
from the combination of other drugs with radiotherapy,
which may be favourable even in the case of an
overexpression of BCL-2 and since platinum derivatives are
not substrates of the multidrug efflux pump (18, 30).
In conclusion, the present study has revealed that the
overexpression of BCL-2 and MDR1 is of potential
predictive value as regards the inefficacy of paclitaxel-based
chemoradiotherapy in NSCLC. 
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